Organ Allocation in Liver Transplantation: Ethics, Organ Supply, and Evidencebased Practice

Medical Care of the Liver Transplant Patient: 4th Edition

Volumn , Issue , 2012, Pages 75-87

  Siparsky, Nicole ^a   Axelrod, David ^a   Freeman, Richard B ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Allocation; Distribution; Donor service area; Equity; High risk grafts; Justice; Survival benefit; Utility

Indexed keywords

EID: 84885564644     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444398441.ch7     Document Type: Chapter

References (54)

1. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010;10:1420-7.
2. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefi t of liver transplantation. Am J Transplant 2005;2:307-13.
3. Merion RM, Guidinger MK, Newmann JM, Ellison MD, Port FK, Wolfe RA. Prevalence and outcomes of multiple-listing for cadaveric kidney and liver transplantation. Am J Transplant 2004;4:94-100.
4. Perut V, Conti F, Scatton O, Soubrane O, Calmus Y, Vidal-Trecan G. Might physicians be restricting access to liver transplantation for patients with alcoholic liver disease?. J Hepatol 2009;51:707-14.
5. Trotter JF , Osgood MJ. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. JAMA 2004;291:1871-4.
6. Hayashi PH, Axelrod DA, Galanko J, Salvalaggio PR, Schnitzler M. Regional differences in deceased donor liver transplantation and their implications for organ utilization and allocation. Clin Transplant 2011;25: 156-63.
7. Neuberger J, Gimson A, Davies M, et al. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut 2008;57:252-7.
8. Rogiers X, Sieders E. Split-liver transplantation: an underused resource in liver transplantation. Tran splantation 2008;86:493-9.
9. Freeman RB, Wiesner RH, Harper A, et al. The New Liver Allocation System: moving towards evidence- based transplantation policy. Liver Transplant 2002;8:851-8.
10. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
11. Wiesner RH, Edwards EB, Freeman RB, et al. Model for end stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-6.
12. Schaubel, Sima CS, Goodrich NP , Feng S, Merion RM. The survival benefi t of decreased donor liver transplantation as a function of candidate disease seve rity and donor quality. Am J Transplant 2008;8:419-25.
13. Freeman RB, Harper A, Edwards EB. Liver outcomes under the model for end-stage liver disease and pediatric stage liver disease. Curr Opin Organ Transplant 2005;10:90-4.
14. Schaubel DE, Guidinger MK, Biggins SW , et al. Survival benefi t-based deceased-donor liver allocation. Am J Transplant 2009;9:970-81.
15. Biggins, SW , Kim WR, Terrault NA, et al. Evidencebased incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130:1652-60.
16. Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-10.
17. Luca A, Angermayr B, Bertolini G, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 2007;13: 1174-80.
18. Lu XH, Liu HB, Wang Y, Wang BY , Song M, Sun MJ. Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis. J Gastroenterol Hepatol 2009;24:1547-53.
19. Lewsey JD, Dawwas M, Copley LP , Gimson A, Van der Meulen JH. Developing a prognostic model for 90-day mortality after liver transplantation based on pretransplant recipient factors. Transplantation 2006;82: 898-907.
20. Young AL, Rajagenashan R, Asthana S, et al. The value of MELD and sodium in assessing potential liver transplant recipients in the United Kingdom. Transpl Int 2007;20:331-7.
21. Porte RJ, Lisman T, Tripodi A, Caldwell SH, Trotter JF. The international normalized ratio (INR) in the MELD score: Problems and solutions; the Coagulation in Liver Disease Study Group. Am J Transplant 2010;10: 1349-53.
22. Tripodi A, Chantarangkul V, Primignani M, et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007;46:520-7.
23. Heuman DM, Mihas AA, Habib A, et al. MELD-XI: a rational approach to "sickest fi rst" liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transpl 2007;13:30-7.
24. Sharma P, Schaubel DE, Sima CS, Merion RM, Lok AS. Re-weighting the model for end-stage liver disease score components. Gastroenterology 2008;135:1575-81.
25. Cholongitas E, Marelli L, Kerry A, et al. Different methods of creatinine measurement signifi cantly affect MELD scores. Liver Transpl 2007;13:523-9.
26. Bambha K, Kim WR, Kremers WK, et al. Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplantation 2004;4:1798-1804.
27. Cholongitas E, Marelli L, Kerry A, et al. Female liver transplant recipients with the same GFR as male recipients have lower MELD scores-a systematic bias. Am J Transplant 2007;7:685-92.
28. Moylan CA, Brady CW , Johnson JL, et al. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 2008;300: 2371-8.
29. Davis CL, Feng S, Sung R, et al. Simultaneous liver-kidney transplantation: evaluation to decision making. Am J Transplant 2007;7:1702-9.
30. Tanriover B, Mejia A, Weinstein J, et al. Analysis of kidney function and biopsy results in liver failure patients with renal dysfunction: a new look to combined liver kidney allocation in the post-MELD era. Transplantation 2008;86:1548-53.
31. Ruiz R, Jennings LW , Kim P, et al. Indications for combined liver and kidney transplantation: propositions after a 23-yr experience. Clin Transplant 2010; 24:807-11.
32. Charlton MR, Wall WJ, Ojo AO, et al. Report of the fi rst international liver transplantation society expert panel consensus conference on renal insuffi ciency in liver transplantation. International Liver Transplantation Society Expert Panel. Liver Transpl 2009;15:S1-34.
33. Llovet JM, Fuster J, Bruix J. Intention to treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-40.
34. Figueras J, Jaurrieta E, Valls C, et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg 2000;190:580-7.
35. Hemming AW , Cattral MS, Reed AI, et al. Liver Transplantation for hepatocellular carcinoma. Ann Surg 2001;233:652-9.
36. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
37. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientifi c registry of transplant recipients database. Hepatology 2008;49:832-8.
38. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006;12: 1761-9.
39. Mazzaferro V, Llovet JM, Miceli R, et al. for the Metroticket Investigator Study Group. Predicting surend vival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10:35-43.
40. Volk M, Marrero JA. Liver transplantation for hepatocellular carcinoma: who benefi ts and who is harmed?. Gastroenterology 2008;134:1612-14.
41. Freeman RB, Gish RG, Harper A, et al. Model for end stage liver disease (MELD exception guidelines: Results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transplantation 2006;12(Suppl 3 ):S128-36.
42. Metzger RA, Delmonico FL, Feng S, et al. Expanded criteria donors for kidney transplantation. Am J Transplant 2003;3(Suppl 4 ):114-25.
43. See http://optn.transplant.hrsa.gov/policiesAndBylaws/ policies.asp for ECD kidney allocation policy (accessed May 20, 2010)
44. Merion RM, Ashby VB, Wolfe RA, et al. Deceaseddonor characteristics and the survival benefi t of kidney transplantation. JAMA 2005;294:2726-33.
45. Feng S, Goodrich NP , Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783-90.
46. Bonney GK, Aldersley MA, Asthana S, et al. Donor risk index and MELD interactions in predicting long-term graft survival: a single-centre experience. Transplantation 2009;87:1858-63.
47. Volk ML, Lok AS, Pelletier SJ, Ubel PA , Hayward RA. Impact of the model for end-stage liver disease alloca tion policy on the use of high-risk organs for liver transplantation. Gastroenterology 2008;135: 1568-74.
48. Halldorson JB, Bakthavatsalam R, Fix O, Reyes JD, Perkins JD. D-MELD, a simple predictor of post liver transplant mortality for optimization of donor/recipient matching. Am J Transplant 2009;9:318-26.
49. Merion RM, Rush SH, Zinsser DM, Goodrich N, Freeman RB, Wolfe RA. Predicted lifetimes for adult and pediatric split liver versus adult whole liver transplant recipients. Am J Transplant 2004;4: 1792-7.
50. Cescon M, Grazi GL, Ravaioli M, et al. Conventional split liver transplantation for two adult recipients: a recent experience in a single European center. Transplantation 2009;88:1117-22.
51. Emond JC, Freeman RB Jr , Renz JF , Yersiz H, Rogiers X, Busuttil RW. Optimizing the use of donated cadaver livers: analysis and policy development to increase the application of split-liver transplantation. Liver Transpl 2002;8:863-72.
52. For a full description of current OPTN policies see: http://www.optn.org/PoliciesandBylaws/policies/docs/ policy_8.doc
53. Mangus RS, Fridell JA, Vianna RM, et al. No difference in clinical transplant outcomes for local and important liver allografts. Liver Transpl 2009;15:640-7.
54. Freeman RB, Harper AM, Edwards EB. Redrawing organ distribution boundaries: Results of a computer simulated analysis for liver transplantation. Liver Transpl 2002;8:659-66.